Birmingham, AL2 Active Studies

Polycystic Kidney Disease Clinical Trials in Birmingham, AL

Find 2 actively recruiting polycystic kidney disease clinical trials in Birmingham, AL. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
64
Enrolling

Recruiting Polycystic Kidney Disease Studies in Birmingham

About Polycystic Kidney Disease Clinical Trials in Birmingham

Polycystic kidney disease (PKD) is a genetic disorder causing numerous fluid-filled cysts to grow in the kidneys, leading to kidney enlargement and progressive loss of function. Autosomal dominant PKD is the most common form. Treatment includes tolvaptan and management of complications.

There are currently 2 polycystic kidney disease clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 64 participants. Research is being sponsored by AstraZeneca, Vertex Pharmaceuticals Incorporated. Clinical trial participation is free and participants receive study-related medical care at no cost.

Polycystic Kidney Disease Clinical Trials in Birmingham — FAQ

Are there polycystic kidney disease clinical trials in Birmingham?

Yes, there are 2 polycystic kidney disease clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What polycystic kidney disease treatments are being tested?

The 2 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for polycystic kidney disease.

Data updated July 18, 2026 from ClinicalTrials.gov